ASCO 2021 | Ribociclib plus everolimus in advanced dedifferentiated liposarcoma

Margaret von Mehren, MD, Fox Chase Cancer Center, Philadelphia, PA, shares the findings of a Phase II trial (NCT03114527) of ribociclib combined with everolimus in patients with dedifferentiated liposarcoma (DDL). In tumor models, ribociclib and everolimus have shown synergistic growth inhibition, leading to the hypothesis that the combination could be of benefit to patients with DDL. Of 19 evaluable patients, 42% met the primary endpoint of non-progression at 16 weeks. A partial response rate of 10% was achieved. The combination was well tolerated, with the most common adverse events being lymphopenia and neutropenia. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.